| scholarly article | Q13442814 |
| P50 | author | Nancy Coover Andreasen | Q4065393 |
| Vincent A. Magnotta | Q26932611 | ||
| Beng-Choon Ho | Q56246054 | ||
| P2093 | author name string | Ronald Pierson | |
| Steven Ziebell | |||
| P2860 | cites work | Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys | Q24654374 |
| Reduced dendritic spine density in auditory cortex of subjects with schizophrenia | Q24658134 | ||
| Effect of antipsychotics on regional cerebral blood flow measured with positron emission tomography | Q48609948 | ||
| Brain volume changes in schizophrenia: how do they arise? What do they mean? | Q48653346 | ||
| Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia | Q48660056 | ||
| Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment | Q49048938 | ||
| Insular cortex abnormalities in schizophrenia: Relationship to symptoms and typical neuroleptic exposure | Q49061545 | ||
| National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. | Q51801492 | ||
| Effects of atypical and typical neuroleptics on anterior cingulate volume in schizophrenia. | Q51925921 | ||
| Morphometry of the superior temporal plane in schizophrenia: relationship to clinical correlates. | Q51937304 | ||
| The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. | Q52042140 | ||
| The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance | Q52112284 | ||
| Psychosis and brain volume changes during the first five years of schizophrenia | Q60610021 | ||
| The Iowa prospective longitudinal study of recent-onset psychoses | Q67563066 | ||
| Dose equivalence of the antipsychotic drugs | Q70058149 | ||
| Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine | Q72540541 | ||
| Total nerve cell number in neocortex in chronic schizophrenics and controls estimated using optical disectors | Q72734923 | ||
| Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia | Q30994462 | ||
| The effects of antipsychotic treatment on cerebral structure and function in schizophrenia | Q31120604 | ||
| What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia | Q31147040 | ||
| Antipsychotic treatment induces alterations in dendrite- and spine-associated proteins in dopamine-rich areas of the primate cerebral cortex | Q31864319 | ||
| Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study | Q33181630 | ||
| Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings | Q33425487 | ||
| Results of a longitudinal analysis of national data to examine relationships between organizational and market characteristics and changes in antipsychotic prescribing in US nursing homes from 1996 through 2006. | Q33483929 | ||
| The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia?--a systematic review. | Q33494667 | ||
| Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia | Q33754399 | ||
| Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: a longitudinal magnetic resonance imaging study | Q33983993 | ||
| The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys | Q33985626 | ||
| Mapping cortical change across the human life span | Q34172914 | ||
| Antipsychotic drug effects on brain morphology in first-episode psychosis | Q34408860 | ||
| Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia | Q34482389 | ||
| Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys | Q34576434 | ||
| Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia | Q34706991 | ||
| Validity of symptom assessment in psychotic disorders: information variance across different sources of history | Q35751934 | ||
| Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia | Q36395044 | ||
| Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. | Q36914354 | ||
| Who are the new users of antipsychotic medications? | Q37337653 | ||
| Neuroleptic withdrawal in schizophrenic patients. A review of the literature | Q40602444 | ||
| Longitudinal study of brain morphology in first episode schizophrenia | Q40718665 | ||
| Magnetic resonance imaging abnormalities in lenticular nuclei and cerebral cortex in schizophrenia | Q41168210 | ||
| Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia | Q43582604 | ||
| The effects of neuroleptic medications on basal ganglia blood flow in schizophreniform disorders: a comparison between the neuroleptic-naïve and medicated states | Q44193616 | ||
| Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. | Q45307345 | ||
| Dysregulated brain development in adult men with schizophrenia: a magnetic resonance imaging study | Q46273440 | ||
| Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics | Q48134165 | ||
| Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry | Q48229217 | ||
| Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study | Q48258798 | ||
| Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. | Q48286419 | ||
| Brain volume changes in first-episode schizophrenia: a 1-year follow-up study | Q48452819 | ||
| Decreased caudate volume in neuroleptic-naive psychotic patients | Q48454154 | ||
| A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures | Q48519543 | ||
| Subcortical and temporal structures in affective disorder and schizophrenia: a magnetic resonance imaging study | Q48539180 | ||
| The effects of antipsychotics on brain structure: what have we learnt from structural imaging of schizophrenia? | Q48596750 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 128-137 | |
| P577 | publication date | 2011-02-01 | |
| P1433 | published in | JAMA Psychiatry | Q635830 |
| P1476 | title | Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia | |
| P478 | volume | 68 |
| Q48496797 | 'Prodromal' diagnosis of psychosis: Ethical problems in research and clinical practice |
| Q40706433 | A History of Psychosis in Bipolar Disorder is Associated With Gray Matter Volume Reduction |
| Q58106866 | A Place for Subjectivity in Psychiatry |
| Q89544041 | A Prospective Longitudinal Investigation of Cortical Thickness and Gyrification in Schizophrenia |
| Q36600804 | A Review of Brain-derived Neurotrophic Factor as a Candidate Biomarker in Schizophrenia |
| Q47635161 | A brain-wide association study of DISC1 genetic variants reveals a relationship with the structure and functional connectivity of the precuneus in schizophrenia. |
| Q36049650 | A framework for interpreting functional networks in schizophrenia |
| Q28539784 | A longitudinal study of alterations of hippocampal volumes and serum BDNF levels in association to atypical antipsychotics in a sample of first-episode patients with schizophrenia |
| Q48681125 | A longitudinal study of cortical changes and their cognitive correlates in patients followed up after first-episode psychosis |
| Q36692829 | A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia. |
| Q38629163 | A neurodevelopment and neuroplasticity-based framework for early intervention in psychotic disorders. |
| Q21558428 | A review of structural neuroimaging in schizophrenia: from connectivity to connectomics |
| Q24288871 | A systematic examination of brain volumetric abnormalities in recent-onset schizophrenia using voxel-based, surface-based and region-of-interest-based morphometric analyses |
| Q38194900 | A systematic review of antipsychotic drug effects on human gene expression related to risk factors for cardiovascular disease |
| Q91048454 | A transdiagnostic neuroanatomical signature of psychiatric illness |
| Q89091254 | A within-subject consideration of the psychotic spectrum disorder concept in a patient in remission associated with cortical gray matter recovery |
| Q44277658 | Aberrations in the arcuate fasciculus are associated with auditory verbal hallucinations in psychotic and in non-psychotic individuals |
| Q35783530 | Abnormalities in structural covariance of cortical gyrification in schizophrenia |
| Q26741515 | Aerobic Exercise as a Tool to Improve Hippocampal Plasticity and Function in Humans: Practical Implications for Mental Health Treatment |
| Q36579982 | Age at First Episode Modulates Diagnosis-Related Structural Brain Abnormalities in Psychosis |
| Q40994321 | Age-related cortical thickness trajectories in first episode psychosis patients presenting with early persistent negative symptoms. |
| Q42278927 | Age-related increase in the number of oligodendrocytes is dysregulated in schizophrenia and mood disorders |
| Q47882769 | Alcohol use is associated with thinner cerebral cortex and larger ventricles in schizophrenia, bipolar disorder and healthy controls |
| Q31155367 | Alteration of gray matter microstructure in schizophrenia |
| Q36817204 | Altered Thalamo-Cortical White Matter Connectivity: Probabilistic Tractography Study in Clinical-High Risk for Psychosis and First-Episode Psychosis |
| Q34700949 | Altered cortical thickness related to clinical severity but not the untreated disease duration in schizophrenia. |
| Q39133107 | An Auto-Ethnographic Study of "Open Dialogue": The Illumination of Snow |
| Q48007135 | An investigation of regional cerebral blood flow and tissue structure changes after acute administration of antipsychotics in healthy male volunteers |
| Q34589580 | Anatomical abnormalities in gray and white matter of the cortical surface in persons with schizophrenia |
| Q57519639 | Antidepressant, antipsychotic and psychological interventions in subjects at high clinical risk for psychosis: OASIS 6-year naturalistic study |
| Q45290173 | Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease |
| Q50759017 | Antipsychotic drugs for prevention of relapse. |
| Q38084211 | Antipsychotic interventions in prodromal psychosis: safety issues |
| Q36915452 | Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes |
| Q33777656 | Antipsychotics activate mTORC1-dependent translation to enhance neuronal morphological complexity |
| Q53092564 | Antipsychotics decrease response confidence. |
| Q57825253 | Are structural brain changes in schizophrenia related to antipsychotic medication? A narrative review of the evidence from a clinical perspective |
| Q41687584 | Aripiprazole and Riluzole treatment alters behavior and neurometabolites in young ADHD rats: a longitudinal 1H-NMR spectroscopy study at 11.7T |
| Q47741746 | Association between using medications with anticholinergic properties and short-term cognitive decline among older men: A retrospective cohort study in Taiwan |
| Q57039080 | Association of Age at Onset and Longitudinal Course of Prefrontal Function in Youth With Schizophrenia |
| Q92667458 | Association of antidepressants with brain morphology in early stages of psychosis: an imaging genomics approach |
| Q52152130 | Association of serum VEGF levels with prefrontal cortex volume in schizophrenia. |
| Q52600030 | Associations between adolescent cannabis use and brain structure in psychosis. |
| Q47583502 | Associations between psychosis endophenotypes across brain functional, structural, and cognitive domains. |
| Q37956422 | Atypical mood stabilizers: a new role for neuroleptics? |
| Q35852767 | Autophagy inhibition uncovers the neurotoxic action of the antipsychotic drug olanzapine. |
| Q90176158 | BDNF Serum Levels are Associated With White Matter Microstructure in Schizophrenia - A Pilot Study |
| Q33566832 | BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysis |
| Q97521512 | Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder |
| Q70851694 | Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review |
| Q37971465 | Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment. |
| Q34447051 | Biomarkers and clinical staging in psychiatry |
| Q37124940 | Brain Biomarkers of Vulnerability and Progression to Psychosis |
| Q26786247 | Brain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter Systems |
| Q26786253 | Brain Structural Effects of Antipsychotic Treatment in Schizophrenia: A Systematic Review |
| Q26786245 | Brain Structural Effects of Psychopharmacological Treatment in Bipolar Disorder |
| Q47386048 | Brain Structure Biomarkers in the Psychosis Biotypes: Findings From the Bipolar-Schizophrenia Network for Intermediate Phenotypes |
| Q36148488 | Brain Structure in Neuropsychologically Defined Subgroups of Schizophrenia and Psychotic Bipolar Disorder |
| Q50419808 | Brain Subtyping Enhances The Neuroanatomical Discrimination of Schizophrenia. |
| Q48118494 | Brain TSPO imaging and gray matter volume in schizophrenia patients and in people at ultra high risk of psychosis: An [(11)C]PBR28 study |
| Q36660287 | Brain gray matter phenotypes across the psychosis dimension |
| Q33948574 | Brain tissue changes and antipsychotic medication |
| Q47859361 | Brain volume change in first-episode psychosis: an effect of antipsychotic medication independent of BMI change |
| Q48243224 | Brain volume changes over the first year of treatment in schizophrenia: relationships to antipsychotic treatment |
| Q38762872 | Brain-imaging studies of treatment-resistant schizophrenia: a systematic review |
| Q45071432 | Can long-term treatment with antipsychotic drugs lead to structural brain damage? Against |
| Q34899462 | Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. |
| Q30558464 | Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence |
| Q33699076 | Cavum septum pellucidum and first-episode psychosis: A meta-analysis. |
| Q34556900 | Cerebellar Morphology and Procedural Learning Impairment in Neuroleptic-Naive Youth at Ultrahigh Risk of Psychosis |
| Q34021040 | Challenges associated with application of clinical staging models to psychotic disorders |
| Q48608193 | Chances and problems of the recovery approach from a psychiatric viewpoint |
| Q94600188 | Characteristics of gray matter alterations in never-treated and treated chronic schizophrenia patients |
| Q48358415 | Characterization of white matter abnormalities in early-stage schizophrenia |
| Q37412453 | Chronic exposure to haloperidol and olanzapine leads to common and divergent shape changes in the rat hippocampus in the absence of grey-matter volume loss |
| Q55437545 | Classification of multi-site MR images in the presence of heterogeneity using multi-task learning☆. |
| Q35109168 | Clinical predictors of therapeutic response to antipsychotics in schizophrenia |
| Q38163315 | Clinical problems encountered in the treatment of adolescents with anorexia nervosa |
| Q38026886 | Clozapine for the treatment of schizophrenia |
| Q22251382 | Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis |
| Q95386203 | Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: an exploratory trial |
| Q50660859 | Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. |
| Q39566093 | Connectivity of the anterior insula differentiates participants with first-episode schizophrenia spectrum disorders from controls: a machine-learning study. |
| Q39070362 | Connectomic correlates of response to treatment in first-episode psychosis. |
| Q54965265 | Corpus callosum volumes in the 5 years following the first-episode of schizophrenia: Effects of antipsychotics, chronicity and maturation. |
| Q34274338 | Correlating anterior insula gray matter volume changes in young people with clinical and neurocognitive outcomes: an MRI study |
| Q34701018 | Correlations between brain structure and symptom dimensions of psychosis in schizophrenia, schizoaffective, and psychotic bipolar I disorders |
| Q55983721 | Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium |
| Q39066784 | Cortical abnormalities in bipolar disorder: an MRI analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working Group |
| Q37622623 | Cortical grey matter volume reduction in people with schizophrenia is associated with neuro-inflammation |
| Q30368997 | Cortical network dysfunction caused by a subtle defect of myelination. |
| Q35818882 | Cortical structural abnormalities in deficit versus nondeficit schizophrenia |
| Q88593547 | Cortical structures and their clinical correlates in antipsychotic-naïve schizophrenia patients before and after 6 weeks of dopamine D2/3 receptor antagonist treatment |
| Q44225154 | Cortical thickness in individuals with non-clinical and clinical psychotic symptoms |
| Q33826006 | Cortical thinning in temporo-parietal junction (TPJ) in non-affective first-episode of psychosis patients with persistent negative symptoms |
| Q39459514 | Critical analysis on the present methods for brain volume measurements in multiple sclerosis |
| Q36096550 | Design and protocol for the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial: a randomised controlled trial. |
| Q41560807 | Detecting neuroimaging biomarkers for schizophrenia: a meta-analysis of multivariate pattern recognition studies |
| Q30459202 | Dexamphetamine selectively increases 40 Hz auditory steady state response power to target and nontarget stimuli in healthy humans |
| Q36167245 | Diagnostic neuroimaging across diseases |
| Q87992766 | Diffusion Imaging of White Matter In Schizophrenia: Progress and Future Directions |
| Q30592331 | Diffusion tensor imaging findings of white matter changes in first episode schizophrenia: a systematic review |
| Q48594731 | Dissociable morphometric differences of the inferior parietal lobule in schizophrenia |
| Q37131018 | Distinguishing prodromal from first-episode psychosis using neuroanatomical single-subject pattern recognition |
| Q35550905 | Divergent effects of first-generation and second-generation antipsychotics on cortical thickness in first-episode psychosis |
| Q34254903 | Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study |
| Q38060256 | Do subjects at clinical high risk for psychosis differ from those with a genetic high risk?--A systematic review of structural and functional brain abnormalities. |
| Q39680515 | Do they see dead people? Cultural factors and sensitivity in screening for schizophrenia spectrum disorders |
| Q50703532 | Does body shaping influence brain shape? Habitual physical activity is linked to brain morphology independent of age. |
| Q52652401 | Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. |
| Q36148481 | Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method |
| Q89022593 | Dynamic Reorganization of Functional Connectivity Reveals Abnormal Temporal Efficiency in Schizophrenia |
| Q48016096 | Dynamic cerebral reorganization in the pathophysiology of schizophrenia: a MRI-derived cortical thickness study. |
| Q91067874 | Dynamic changes of functional segregation and integration in vulnerability and resilience to schizophrenia |
| Q35873850 | Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. |
| Q89891607 | Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial |
| Q34747371 | Effects of age on white matter integrity and negative symptoms in schizophrenia |
| Q48026458 | Effects of childhood trauma on left inferior frontal gyrus function during response inhibition across psychotic disorders |
| Q34068878 | Elevated concentrations of neurofilament light chain in the cerebrospinal fluid of bipolar disorder patients |
| Q57892499 | Engaging People with Psychosis in Acceptance and Commitment Therapy and Mindfulness |
| Q38988333 | Episodic memory functions in first episode psychosis and clinical high risk individuals |
| Q37975281 | Ethical implications for clinical practice and future research in "at risk" individuals. |
| Q57810372 | Ethics of giving antipsychotic medication to at-risk young people |
| Q38613680 | Experiences of antipsychotic use in patients with early psychosis: a two-year follow-up study |
| Q37623597 | Explaining attitudes and adherence to antipsychotic medication: the development of a process model |
| Q50664683 | Extensive brain structural network abnormality in first-episode treatment-naive patients with schizophrenia: morphometrical and covariation study. |
| Q35965893 | Extensive gray matter volume reduction in treatment-resistant schizophrenia. |
| Q39248594 | Extrastriatal dopamine D2/3 receptors and cortical grey matter volumes in antipsychotic-naïve schizophrenia patients before and after initial antipsychotic treatment |
| Q37730408 | Familial and environmental influences on brain volumes in twins with schizophrenia |
| Q50761921 | First, do no harm: confronting the myths of psychiatric drugs. |
| Q50556051 | First- and second-generation antipsychotic drug treatment and subcortical brain morphology in schizophrenia. |
| Q38893848 | Forty years of structural imaging in psychosis: promises and truth |
| Q36609798 | Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade |
| Q48453000 | Frontal lobe function and social adjustment in patients with schizophrenia: near-infrared spectroscopy |
| Q92518217 | Functional brain networks in never-treated and treated long-term Ill schizophrenia patients |
| Q37602607 | Future in psychopathology research |
| Q48254506 | GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats |
| Q45988102 | Genetic Overlap Between Schizophrenia and Volumes of Hippocampus, Putamen, and Intracranial Volume Indicates Shared Molecular Genetic Mechanisms. |
| Q37196005 | Genome-wide association analysis with gray matter volume as a quantitative phenotype in first-episode treatment-naïve patients with schizophrenia |
| Q47668735 | Gray matter changes and cognitive predictors of 2-year follow-up abnormalities in early-onset first-episode psychosis |
| Q48895267 | Gray matter volume as an intermediate phenotype for psychosis: Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). |
| Q24606392 | Gray matter volume in schizophrenia and bipolar disorder with psychotic features |
| Q36960391 | Heritability of multivariate gray matter measures in schizophrenia |
| Q36377853 | Hippocampal Shape Abnormalities Predict Symptom Progression in Neuroleptic-Free Youth at Ultrahigh Risk for Psychosis |
| Q49616477 | Hippocampal Subregions Across the Psychosis Spectrum |
| Q36390750 | Hippocampal shape and volume changes with antipsychotics in early stage psychotic illness |
| Q34700980 | Hippocampal volume is reduced in schizophrenia and schizoaffective disorder but not in psychotic bipolar I disorder demonstrated by both manual tracing and automated parcellation (FreeSurfer). |
| Q31054567 | History of the Concept of Disconnectivity in Schizophrenia |
| Q28087255 | How Schizophrenia Develops: Cognitive and Brain Mechanisms Underlying Onset of Psychosis |
| Q35610726 | How can neuroimaging facilitate the diagnosis and stratification of patients with psychosis? |
| Q86708206 | How effective are the current treatments for children diagnosed with manic/mixed bipolar disorder? |
| Q49083694 | Hypothalamus and pituitary volume in schizophrenia: a structural MRI study |
| Q23890289 | Identification of a common neurobiological substrate for mental illness |
| Q36304801 | Imaging Genetics and Genomics in Psychiatry: A Critical Review of Progress and Potential |
| Q47871481 | Immediate-Early Genes Modulation by Antipsychotics: Translational Implications for a Putative Gateway to Drug-Induced Long-Term Brain Changes. |
| Q41084707 | Impact of polygenic schizophrenia-related risk and hippocampal volumes on the onset of psychosis |
| Q38955513 | Improving Current Treatments for Schizophrenia |
| Q42358625 | In search of an evidence-based role for psychiatry |
| Q92950030 | Individual Alpha Peak Frequency Moderates Transfer of Learning in Cognitive Remediation of Schizophrenia |
| Q36066670 | Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers |
| Q93069431 | Inefficient neural system stabilization: a theory of spontaneous resolutions and recurrent relapses in psychosis |
| Q36828285 | Influence of Antipsychotic and Anticholinergic Loads on Cognitive Functions in Patients with Schizophrenia |
| Q89572022 | Influence of More Than 5 Years of Continuous Exposure to Antipsychotics on Cerebral Functional Connectivity of Chronic Schizophrenia |
| Q37367250 | Influence of ZNF804a on brain structure volumes and symptom severity in individuals with schizophrenia. |
| Q36145094 | Insular volume abnormalities associated with different transition probabilities to psychosis |
| Q35878916 | Intact relational memory and normal hippocampal structure in the early stage of psychosis |
| Q91320613 | Integrating machining learning and multimodal neuroimaging to detect schizophrenia at the level of the individual |
| Q38376655 | Is duration of illness really influencing outcome in major psychoses? |
| Q36260919 | Joint Coupling of Awake EEG Frequency Activity and MRI Gray Matter Volumes in the Psychosis Dimension: A BSNIP Study |
| Q48364325 | Key functional circuitry altered in schizophrenia involves parietal regions associated with sense of self |
| Q36148454 | Lack of Evidence for Regional Brain Volume or Cortical Thickness Abnormalities in Youths at Clinical High Risk for Psychosis: Findings From the Longitudinal Youth at Risk Study |
| Q89088687 | Linked 4-Way Multimodal Brain Differences in Schizophrenia in a Large Chinese Han Population |
| Q33655392 | Local gyrification index in probands with psychotic disorders and their first-degree relatives |
| Q33853511 | Long term antipsychotic treatment does not alter metabolite concentrations in rat striatum: an in vivo magnetic resonance spectroscopy study. |
| Q34681347 | Long-term antipsychotic use and brain changes in schizophrenia - a systematic review and meta-analysis |
| Q70846418 | Long-term harms from previous use of selective serotonin reuptake inhibitors: A systematic review |
| Q35217858 | Longer lithium exposure is associated with better white matter integrity in older adults with bipolar disorder |
| Q33921159 | Longitudinal changes in total brain volume in schizophrenia: relation to symptom severity, cognition and antipsychotic medication |
| Q48466370 | Longitudinal follow-up of cavum septum pellucidum and adhesio interthalamica alterations in first-episode psychosis: a population-based MRI study |
| Q36157849 | Longitudinal regional brain volume loss in schizophrenia: Relationship to antipsychotic medication and change in social function |
| Q46147870 | Longitudinal study of cerebral surface morphology in youth with 22q11.2 deletion syndrome, and association with positive symptoms of psychosis |
| Q37358080 | MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse |
| Q55508141 | Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: systematic review. |
| Q92932105 | Mechanisms and therapeutic significance of autophagy modulation by antipsychotic drugs |
| Q33762467 | Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis? |
| Q35909333 | Metacognition-augmented cognitive remediation training reduces jumping to conclusions and overconfidence but not neurocognitive deficits in psychosis |
| Q92245093 | Micro- and Macrostructural White Matter Integrity in Never-Treated and Currently Unmedicated Patients With Schizophrenia and Effects of Short-Term Antipsychotic Treatment |
| Q28265163 | Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment |
| Q47841028 | Modular-level alterations of structure-function coupling in schizophrenia connectome. |
| Q37262794 | Morphological Alterations in the Thalamus, Striatum, and Pallidum in Autism Spectrum Disorder. |
| Q92417080 | Morphological Profiling of Schizophrenia: Cluster Analysis of MRI-Based Cortical Thickness Data |
| Q89959086 | Motor abnormalities and basal ganglia in first-episode psychosis (FEP) |
| Q50420417 | Multivariate Associations Among Behavioral, Clinical, and Multimodal Imaging Phenotypes in Patients With Psychosis. |
| Q50573955 | NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. |
| Q64085430 | Nerve Growth Factor Serum Levels Are Associated With Regional Gray Matter Volume Differences in Schizophrenia Patients |
| Q89320261 | Neural correlates of global and specific cognitive deficits in schizophrenia |
| Q38310750 | Neural oscillations as a translational tool in schizophrenia research: rationale, paradigms and challenges |
| Q41920722 | Neuroanatomical classification in a population-based sample of psychotic major depression and bipolar I disorder with 1 year of diagnostic stability |
| Q36386404 | Neuroanatomical maps of psychosis onset: voxel-wise meta-analysis of antipsychotic-naive VBM studies |
| Q46146851 | Neuroanatomical markers of genetic liability to psychosis and first episode psychosis: a voxelwise meta-analytical comparison |
| Q38026435 | Neurobiological correlates of delusion: beyond the salience attribution hypothesis |
| Q38175169 | Neurobiological effects of physical exercise in schizophrenia: a systematic review |
| Q37981491 | Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments |
| Q36378169 | Neuroimaging predictors of functional outcomes in schizophrenia at baseline and 6-month follow-up |
| Q47382752 | Neuroprogression and episode recurrence in bipolar I disorder: A study of gray matter volume changes in first-episode mania and association with clinical outcome |
| Q35505540 | Neuropsychology, autobiographical memory, and hippocampal volume in "younger" and "older" patients with chronic schizophrenia |
| Q30582343 | Neuropsychopharmacology of auditory hallucinations: insights from pharmacological functional MRI and perspectives for future research |
| Q50556987 | No progressive brain changes during a 1-year follow-up of patients with first-episode psychosis. |
| Q42347518 | On discontinuing treatment in schizophrenia: a clinical conundrum |
| Q47322741 | Optical coherence tomography indices of structural retinal pathology in schizophrenia |
| Q38086645 | Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment |
| Q35999354 | Patients with Schizophrenia Fail to Up-Regulate Task-Positive and Down-Regulate Task-Negative Brain Networks: An fMRI Study Using an ICA Analysis Approach |
| Q34041815 | Patients with poor response to antipsychotics have a more severe pattern of frontal atrophy: a voxel-based morphometry study of treatment resistance in schizophrenia |
| Q39646600 | Patterns of regional gray matter loss at different stages of schizophrenia: A multisite, cross-sectional VBM study in first-episode and chronic illness |
| Q58276450 | Perphenazine and trifluoperazine induce mitochondria-mediated cell death in SH-SY5Y cells |
| Q50527605 | Personal Accounts of Discontinuing Neuroleptic Medication for Psychosis. |
| Q34807152 | Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia |
| Q34274859 | Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents |
| Q92080750 | Positive and Negative Effects of Antipsychotic Medication: An International Online Survey of 832 Recipients |
| Q31095968 | Predicting individualized clinical measures by a generalized prediction framework and multimodal fusion of MRI data |
| Q44658919 | Prefrontal cortical thinning links to negative symptoms in schizophrenia via the ENIGMA consortium. |
| Q30529640 | Prefrontal gray matter morphology mediates the association between serum anticholinergicity and cognitive functioning in early course schizophrenia |
| Q64113447 | Prognostic Utility of Multivariate Morphometry in Schizophrenia |
| Q35960362 | Progressive Brain Atrophy and Cortical Thinning in Schizophrenia after Commencing Clozapine Treatment |
| Q36395044 | Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia |
| Q34351095 | Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. |
| Q24626182 | Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies |
| Q34691699 | Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk |
| Q91731927 | Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment |
| Q58122155 | Propionate Protects Haloperidol-Induced Neurite Lesions Mediated by Neuropeptide Y |
| Q38399332 | Proteome and pathway effects of chronic haloperidol treatment in mouse hippocampus. |
| Q38984616 | Psychiatrist's adherence: a new factor in relapse prevention of schizophrenia. A randomized controlled study on relapse control through telemedicine system |
| Q31137558 | Psychoradiology: The Frontier of Neuroimaging in Psychiatry. |
| Q34467748 | Qualitative investigation of targets for and barriers to interventions to prevent psychosis relapse |
| Q38911287 | Quantifying the Interaction and Contribution of Multiple Datasets in Fusion: Application to the Detection of Schizophrenia |
| Q42374185 | Real-world effectiveness of antipsychotics |
| Q34337272 | Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. |
| Q48189224 | Relationships between corpus callosum and language lateralization in patients with schizophrenia and bipolar disorders |
| Q46567488 | Response to Targeted Cognitive Training Correlates with Change in Thalamic Volume in a Randomized Trial for Early Schizophrenia |
| Q37451498 | Resting-state fMRI connectivity impairment in schizophrenia and bipolar disorder |
| Q59129268 | Resting-state gamma-band power alterations in schizophrenia reveal E/I-balance abnormalities across illness-stages |
| Q26776255 | Rethinking psychopharmacotherapy: The role of treatment context and brain plasticity in antidepressant and antipsychotic interventions |
| Q57312955 | Risk of dementia associated with psychotic disorders in later life: the health in men study (HIMS) |
| Q92282698 | Role of D3 dopamine receptors in modulating neuroanatomical changes in response to antipsychotic administration |
| Q56959104 | Schizophrenia |
| Q104134881 | Schizophrenia polygenic risk predicts general cognitive deficit but not cognitive decline in healthy older adults |
| Q47677836 | Schizophrenia: Basic and Clinical |
| Q34023115 | Schizophrenia: an integrated sociodevelopmental-cognitive model |
| Q47834944 | Shared and distinct alterations of white matter tracts in remitted and nonremitted patients with schizophrenia. |
| Q42362623 | Short-term mechanisms influencing volumetric brain dynamics |
| Q34635905 | Should attenuated psychosis syndrome be included in DSM-5? |
| Q47301729 | State-dependent microstructural white matter changes in drug-naïve patients with first-episode psychosis. |
| Q34250017 | Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies |
| Q39271880 | Striatal shape abnormalities as novel neurodevelopmental endophenotypes in schizophrenia: a longitudinal study. |
| Q36117393 | Structural abnormalities in the cuneus associated with Herpes Simplex Virus (type 1) infection in people at ultra high risk of developing psychosis |
| Q59135280 | Structural and functional brain abnormalities in drug-naive, first-episode, and chronic patients with schizophrenia: a multimodal MRI study |
| Q34341124 | Structural and functional neuroimaging studies in major depressive disorder with psychotic features: a critical review |
| Q37131057 | Structural brain alterations associated with schizophrenia preceded by conduct disorder: a common and distinct subtype of schizophrenia? |
| Q34393431 | Structural brain changes associated with antipsychotic treatment in schizophrenia as revealed by voxel-based morphometric MRI: an activation likelihood estimation meta-analysis |
| Q36348922 | Structural brain changes in schizophrenia at different stages of the illness: A selective review of longitudinal magnetic resonance imaging studies |
| Q30668157 | Structural correlates of formal thought disorder in schizophrenia: An ultra-high field multivariate morphometry study |
| Q88577624 | Structural covariance and cortical reorganisation in schizophrenia: a MRI-based morphometric study |
| Q38812229 | Structural neuroimaging across early-stage psychosis: Aberrations in neurobiological trajectories and implications for the staging model. |
| Q23747506 | Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium |
| Q36395488 | Successful management of clozapine adverse effects with extended (alternate day) antipsychotic dosing in a patient with schizophrenia |
| Q37202142 | Supervised, Multivariate, Whole-Brain Reduction Did Not Help to Achieve High Classification Performance in Schizophrenia Research |
| Q48901567 | Surface-based brain morphometry and diffusion tensor imaging in schizoaffective disorder |
| Q34564212 | Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II |
| Q48481845 | Swertisin ameliorates pre-pulse inhibition deficits and cognitive impairment induced by MK-801 in mice |
| Q50205158 | Symptoms, functioning and coping strategies in individuals with schizophrenia spectrum disorders who do not take antipsychotic medication: a comparative interview study. |
| Q41156644 | Targeted intermittent treatment in chronic schizophrenia |
| Q28077138 | The Longitudinal Course of Schizophrenia Across the Lifespan: Clinical, Cognitive, and Neurobiological Aspects |
| Q38570636 | The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics |
| Q34649187 | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder |
| Q36591384 | The association of white matter volume in psychotic disorders with genotypic variation in NRG1, MOG and CNP: a voxel-based analysis in affected individuals and their unaffected relatives |
| Q90728397 | The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia |
| Q44668111 | The effect of aerobic exercise on cortical architecture in patients with chronic schizophrenia: a randomized controlled MRI study. |
| Q47155737 | The effect of duration of illness and antipsychotics on subcortical volumes in schizophrenia: Analysis of 778 subjects |
| Q43032610 | The field of schizophrenia: strengths, weaknesses, opportunities, and threats |
| Q97556098 | The mGluR2/3 agonist pomaglumetad methionil normalizes aberrant dopamine neuron activity via action in the ventral hippocampus |
| Q64950972 | The meaning of group differences in cognitive test performance. |
| Q48318194 | The medicalisation of "ups and downs": the marketing of the new bipolar disorder |
| Q24067152 | The myth of schizophrenia as a progressive brain disease |
| Q38232366 | The neurobiology and treatment of first-episode schizophrenia |
| Q46558915 | The oft-times overlooked "pharmacologic" relapse in schizophrenia |
| Q96302720 | The polygenic architecture of schizophrenia - rethinking pathogenesis and nosology |
| Q38061036 | The psychosis high-risk state: a comprehensive state-of-the-art review |
| Q96773916 | The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia |
| Q34418847 | The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. |
| Q48746770 | The visual cortex in schizophrenia: alterations of gyrification rather than cortical thickness--a combined cortical shape analysis |
| Q30575242 | Three-way (N-way) fusion of brain imaging data based on mCCA+jICA and its application to discriminating schizophrenia |
| Q45775101 | Three-year longitudinal population-based volumetric MRI study in first-episode schizophrenia spectrum patients. |
| Q37230904 | Time-dependent effects of haloperidol on glutamine and GABA homeostasis and astrocyte activity in the rat brain |
| Q26860217 | Translating the MAM model of psychosis to humans |
| Q48231299 | Treatment of delirium with risperidone in cancer patients |
| Q35673737 | Twenty Years of Schizophrenia Research in the Northern Finland Birth Cohort 1966: A Systematic Review |
| Q64231585 | Twenty years of misdiagnosis of schizophrenia in a patient with Dandy-Walker variant syndrome |
| Q89901286 | Two distinct neuroanatomical subtypes of schizophrenia revealed using machine learning |
| Q37896626 | Understanding aberrant white matter development in schizophrenia: an avenue for therapy? |
| Q48628524 | Use of antipsychotic medication and suicidality--the Northern Finland Birth Cohort 1966. |
| Q30686416 | Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: a critical update |
| Q89669017 | Using Open Questions to Understand 650 People's Experiences With Antipsychotic Drugs |
| Q60460701 | Using the cognitive assessment interview to screen cognitive impairment in psychosis |
| Q38697215 | Ventricular volumes across stages of schizophrenia and other psychoses |
| Q38473103 | Verbal learning and memory and their associations with brain morphology and illness course in schizophrenia spectrum psychoses |
| Q48038781 | Views of early psychosis clinicians on discontinuation of antipsychotic medication following symptom remission in first episode psychosis |
| Q43762923 | Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment. |
| Q34034400 | Volumetric changes in the basal ganglia after antipsychotic monotherapy: a systematic review |
| Q33935798 | Voxel-based gray and white matter morphometry correlates of hallucinations in schizophrenia: The superior temporal gyrus does not stand alone |
| Q48569172 | What determines continuing grey matter changes in first-episode schizophrenia and affective psychosis? |
| Q55023835 | What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? |
| Q37272654 | White matter alterations in antipsychotic- and mood stabilizer-naïve individuals with bipolar II/NOS disorder |
| Q34406905 | White matter alterations in bipolar disorder: potential for drug discovery and development |
| Q37705723 | White matter changes associated with antipsychotic treatment in first-episode psychosis |
| Q27686764 | White matter development in the early stages of psychosis. |
| Q37477310 | White matter integrity as a predictor of response to treatment in first episode psychosis |
| Q34778177 | White matter microstructural abnormalities of the cingulum bundle in youths with 22q11.2 deletion syndrome: associations with medication, neuropsychological function, and prodromal symptoms of psychosis |
| Q40119382 | White-matter connectivity related to paliperidone treatment response in patients with schizophrenia |
| Q48148097 | White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment |
| Q48204422 | ZNF804A rs1344706 is associated with cortical thickness, surface area, and cortical volume of the unmedicated first episode schizophrenia and healthy controls |
| Q87117734 | [Can long-term treatment with antipsychotic drugs lead to structural brain damage? Pro] |
| Q87945859 | [Frontal brain volume reduction due to antipsychotic drugs?] |
| Q45958384 | [Personalised medicine in psychiatry and psychotherapy. A review of the current state-of-the-art in the biomarker-based early recognition of psychoses]. |
| Q89919164 | [Pros and cons of antipsychotic drugs in Prodromal stages of schizophrenia] |
| Q60621254 | [Somatic morbidity in the mentally ill] |
| Q50302553 | [The German research network for mental disorders]. |
| Q89363812 | [What role for paraclinical investigations within clinical trials conducted in psychiatric patients?] |
Search more.